What have we learned about optimal induction therapy for lupus nephritis (III through V) from randomized, controlled trials?
Clark
William F
WF
London Health Sciences Centre, and Department of Medicine, University of Western Ontario, London, Canada, N6A 4G5. william.clark@lhsc.on.ca
Sontrop
Jessica M
JM
D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D012720:Severity of Illness Index; D016896:Treatment Outcome
D007166:Immunosuppressive Agents